Symrise stock heads into Q3 update below its 52-week high

Published on 10/04/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Symrise stock was last at EUR 91.00 on Xetra on October 2, 2026, 4.21 percent below its EUR 95.00 yearly high. Q3 results are scheduled for October 28.

Isometrische 3D-Grafik der Wertschöpfungskette von Duftstoffen, Symrise AG DE000SYM9999 — Symrise AG (DE000SYM9999) isometrisches 3D-Diagramm visualisiert Wertschöpfungskette von Rohstoffernte über Destillation bis zum fertigen Duftstoff-Fläschchen, Illustration mit AI erstellt.

Symrise (ISIN DE000SYM9999) was last at EUR 91.00 on Xetra on October 2, 2026 at 5:35 p.m. CEST, placing the stock 4.21 percent below its 52-week high of EUR 95.00. Symrise has scheduled its Q3 2026 interim update for October 28, 2026, giving investors the next firm checkpoint on the group's growth recovery.

First-half growth sets the baseline

Symrise reported first-half 2026 sales of EUR 2.539 billion, with organic growth accelerating to 4.5 percent in the second quarter after a weaker first quarter. According to Yahoo Finance on July 30, 2026, adjusted EBITDA reached EUR 553 million and the adjusted EBITDA margin stood at 21.8 percent.

The cash profile was stronger than the earnings trend alone suggests. Adjusted business free cash flow increased 47 percent year over year to EUR 347 million, lifting the business free cash flow margin to 13.7 percent, while net leverage improved to 2.2 times adjusted EBITDA at June 30, 2026.

Guidance meets the Q3 test

Yahoo Finance reported that Symrise reaffirmed its 2026 outlook on July 30, 2026, including organic sales growth of 2%-4%, an adjusted EBITDA margin of 21.5%-22.5% and an adjusted business free cash flow margin above 14 percent. The 4.5 percent organic growth rate in Q2 is therefore the operating benchmark for the October update.

The main counterweight is uneven segment performance. Scent and Care generated adjusted EBITDA of EUR 178 million in the first half, down 6.7 percent, with its margin falling to 17.7 percent, while Taste, Nutrition and Health increased adjusted EBITDA 0.6 percent to EUR 372 million and expanded its margin to 24.5 percent.

Analyst targets sit above the quote

Analyst expectations provide a second test for the stock. MarketScreener lists an Outperform consensus from 17 analysts, with an average target of EUR 98.63 and a maximum target of EUR 110.00; the minimum target is EUR 75.00, according to MarketScreener. The average target lies 8.38 percent above the EUR 91.00 Xetra price.

Deutsche Bank Research kept its Buy rating and EUR 103.00 target on October 1, 2026. As finanzen.at reported, the bank estimated third-quarter operational growth of 5.3 percent and described that pace as ahead of market expectations.

Stock remains below the yearly peak

Symrise had a market capitalization of EUR 12.5 billion and traded 301,333 shares on October 2, 2026. The EUR 91.00 price compares with a 52-week range of EUR 64.70 to EUR 95.00, so the October 28 update will test whether the second-quarter acceleration can extend into the final months of 2026.